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Previous studies suggest that enterovirus infections
may initiate and accelerate  -cell damage years before
the clinical manifestation of type 1 diabetes. We have
now analyzed the role of enterovirus infections in the
initiation of autoimmunity in children who have tested
positive for diabetes-associated autoantibodies in a
prospective study starting at birth (the Finnish Dia-
betes Prediction and Prevention Study). The frequency
of enterovirus infections was studied using both serol-
ogy and testing for the presence of enterovirus RNA in
the sera of 21 children who developed and retained
autoantibodies and in 104 control subjects chosen from
the same study cohort and matched for the time of birth,
sex, and HLA alleles determining genetic diabetes sus-
ceptibility. Sample intervals were taken as basic units of
follow-up, to which the observed number of infections
was adjusted. Enterovirus infections were detected in
26% of sample intervals in the case subjects and in 18%
of the sample intervals in the control children (P =
0.03). A temporal relationship between enterovirus
infections and the induction of autoimmunity was found;
enterovirus infections were detected in 57% of the case
subjects during a 6-month follow-up period preceding
the ﬁrst appearance of autoantibodies compared with
31% of the matched control children in the same age-
group (odds ratio 3.7, 95% CI 1.2–11.4). The frequency
of adenovirus infections did not differ between the
patient and control groups. Our data imply that
enterovirus infections are associated with the develop-
ment of  -cell autoimmunity and provide evidence for
the role of enteroviruses in the initiation of  -cell
destruction. Diabetes 49:1314–1318, 2000
T
he etiology of type 1 diabetes comprises both
genetic and environmental components. Entero-
virus infections have long been suspected as
potential environmental factors playing a role in
the pathogenesis of type 1 diabetes (1,2). Recent prospective
studies, based on enterovirus serology (3–5) and detection of
enterovirus RNA in sera of prediabetic children (6), suggest
that enterovirus infections may initiate and accelerate the
 -cell–damaging process years before the clinical manifes-
tation of type 1 diabetes. Enterovirus RNA has also been
detected more frequently in patients with newly diagnosed
type 1 diabetes than in healthy control subjects (7–9).
Clear signs of  -cell damage often appear months or years
before the manifestation of clinical diabetes (10), suggesting
that prospective studies starting before the appearance of
autoantibodies may be helpful in studying the etiology of the
disease. In addition, early recognition of the individuals with
ongoing  -cell damage may make it possibile to delay or
halt  -cell destruction. The Finnish Diabetes Prediction and
Prevention (DIPP) Study is a prospective population-based
birth-cohort study in which Finnish children with increased
genetic risk for type 1 diabetes are studied for the appearance
of diabetes-associated autoantibodies at 3- to 12-month
intervals from birth. We have now studied the frequency of
enterovirus infections in 21 DIPP cohort children who devel-
oped autoantibodies during follow-up and in their control
subjects who were matched for the time of birth, sex, and
HLA risk alleles. For comparison, adenovirus infections
were analyzed in the same children. Short sample intervals
during the follow-up, together with a large panel of sensitive
virological assays, create an optimal setting for the evalua-
tion of the role of these infections within the framework of
the present study design.
RESEARCH DESIGN AND METHODS
Subjects. The case subjects and control subjects were participants of the DIPP
Study, which was initiated in Finland in 1994. In this trial, all babies born at
the University Hospitals of Oulu, Tampere, and Turku were screened with
parental permission for type 1 diabetes–associated HLA-DQB1 alleles. The
HLA-DQB1 alleles associated with type 1 diabetes risk or protection were
determined from cord blood samples as previously described (11).
The infants carrying the HLA-DQB1*02/*0302 or the *0302/x genotype (x
referring to other alleles than *02, *0301, or *0602) were then observed from
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birth with an interval of 3–6 months during the first 2 years of life and subse-
quently with an interval of 6–12 months. The follow-up samples were screened
for islet cell antibodies (ICA). All samples from children who test positive for
ICA are then also screened for glutamic acid decarboxylase antibodies
(GADA), insulin autoantibodies (IAA), and tyrosine phosphatase-related IA-2
protein antibodies (IA-2A).
A total of 21 children (10 boys and 11 girls), who were identiﬁed as the ﬁrst
subjects in the DIPP cohort with continuous signs of  -cell damage, were the
case subjects in this study. Type 1 diabetes has subsequently been diagnosed
in 5 of them. The last follow-up sample from the remaining 16 children was pos-
itive for ICA in all of the cases (mean level 69.5 Juvenile Diabetes Foundation
units [JDFU]), GADA in 13 cases (mean level 115.5 relative units [RU]), IAA in
13 cases (mean level 23.1 RU), and IA-2A in 7 cases (mean level 38.4 RU). The
last follow-up sample from these 16 cases was thus positive for 4 autoantibodies
in 6 cases, 3 autoantibodies in 7 cases, 2 autoantibodies in 1 case, and 1 auto-
antibody in 2 children (both have been constantly ICA positive for at least
2 years).
The cases were born between November 1994 and June 1997 and have been
followed from birth. The mean follow-up time was 20 months (range 9–29
months). Samples were drawn at birth (cord blood) and subsequently at 3- to
6-month intervals. Altogether, 20 cord blood samples and 125 follow-up serum
samples from the case children were analyzed. Nine of the patients had the HLA-
DQB1*02/*0302 genotype, and 12 of the patients had the HLA-DQB1*0302/x geno-
type. Of the 21 case children, 4 had a father with type 1 diabetes, whereas all
other ﬁrst-degree relatives of the case children were nondiabetic.
Of the control children, 3–6 (mean 5) matched for the time of birth, sex, and
HLA-DQB1 alleles, were chosen from the DIPP cohort for each case. The
control group comprised 104 children from whom 98 cord blood samples
and 567 follow-up serum samples were analyzed. The control subjects were
followed from birth according to the same protocol as the case subjects.
Their mean follow-up time was 20 months (range 9–31 months). All control
children remained negative for ICA.
In addition to the children’s samples, we also studied serum samples
obtained at the end of the first trimester of pregnancy from the mothers of 20
case children and 103 control children.
Entero- and adenovirus antibody analyses. IgG and IgA class antibodies
against purified Coxackievirus B4 (CVB4), purified echovirus 11 (EV11), and
a synthetic enterovirus peptide antigen (sequence KEVPALTAVETGAT-C
derived from an immunodominant region of capsid protein VP1 [12], which is
a common epitope for several enteroviruses [13]) were measured using
enzyme immunoassay (EIA) as described (3,14). The purified CVB4 and EV11
were incubated at 56°C for 15 min to expose antigenic determinants common
for various enterovirus serotypes. IgG and IgA class antibodies against aden-
ovirus hexon protein were measured in EIA as a control (15).
Microtiter plates (Nunc Immunoplate; Nunc, Glostrup, Denmark) were
coated by the antigens in 1.0 µg/ml (CVB4 and EV11), 1.8 µg/ml (Adeno), and
2.5 µg/ml (bovine serum albumin-conjugated peptide) concentration in car-
bonate buffer (pH 9.4). Serum samples were analyzed in 1/100 (IgA), 1/500 (EV11
IgG) and 1/2000 (other IgG assays) dilution in phosphate-buffered saline (PBS)
supplemented with 1% bovine serum albumin and 0.05% Tween 20. Binding of
antibodies was documented using peroxidase-conjugated antihuman IgG and
IgA (P214 and P216, respectively; Dako, Copenhagen, Denmark).
All serum samples of each child were analyzed in the same assay. Results
of the EIA tests were expressed in enzyme immune units (EIU), which show
the relative antibody reactivity of the sample compared with positive and
negative reference sera included in each assay.
IgM and IgA class enterovirus antibodies were measured against a mixture
of 3 enterovirus antigens (Coxsackievirus B3, Coxsackievirus A16, and EV11)
using a capture EIA method, which is a modification of our previously used
capture radioimmunoassay (RIA) (3,5). Monoclonal anti–human IgM or IgA
antibody–sensitized microtiter plates were purchased from Medix Biochem-
ica (Kauniainen, Finland). Sera were incubated for 90 min at 37°C in 1/100 dilu-
tion of PBS + 1% bovine serum albumin + 0 .05% Tween 20. After washings, the
mixture of heat-treated enterovirus antigens (10 µg/ml for each antigen) was
incubated for 60 min at 37°C, and then a comparable mixture of biotinylated
detection antibodies was added (10 µg/ml for each antibody, 60 min at 37°C).
These detection antibodies were produced by immunizing rabbits by purified
heat-treated Coxsackievirus B3, Coxsackievirus A16, and EV11, respectively.
The IgG fraction of rabbit hyperimmune sera was purified in a fast protein liq-
uid chromatography system using a protein A column (Pharmacia Fine Chem-
icals, Uppsala, Sweden) and then coupled with biotin, according to standard
procedures. After washings, streptavidin-horseradish peroxidase conjugate
(Life Technologies, Gaithersburg, MD) was added (30 min at 37°C) and, as the
final step, the color reaction of the orto-phenylenediamine-dihydrochloride
substrate (30 min at 37°C) was recorded at 492 nm. The samples giving
absorbance values that exceeded the cut-off level for antibody positivity were
reanalyzed using mock-infected cell lysate as antigen and were considered neg-
ative if this reactivity exceeded 50% of that obtained with the virus antigen.
The results obtained by these EIA methods were comparable with those
obtained by the capture RIA (3) when samples from patients with confirmed
enterovirus infections were analyzed.
Detection of enterovirus RNA. RNA was extracted according to the manu-
facturer’s protocol (QIAamp viral RNA kit; Qiagen, Hilden, Germany) from
140 µl of the serum samples. The samples had been stored at –70°C, and they
were thawed for the ﬁrst time for RNA extraction. Reverse transcriptase-poly-
merase chain reaction (RT-PCR) was performed as described (16) using a
primer pair from the highly conserved 5  noncoding region of enteroviruses.
Separate rooms were used for each step of the RT-PCR assay, and positive and
negative controls were included in each assay. The RT-PCR amplicons were
hybridized with a europium-labeled enterovirus-speciﬁc oligonucleotide probe
and a liquid-phase assay on microtiter plate format (16). Europium ﬂuorescence
was measured using time-resolved detection. The sample signal was com-
pared with the mean background ﬂuorescence of the negative controls. A 5-fold
or greater signal-to-background ratio was considered positive, indicating a
current enterovirus infection. All samples positive in the assay were conﬁrmed
to be positive by repeated RT-PCR and subsequent hybridization assay.
Diagnostic criteria for entero- and adenovirus infections. During the fol-
low-up, a 2-fold or greater increase in the antibody level against an antigen,
observed between 2 consecutive samples and exceeding the cut-off level of
seropositivity (15 EIU), was considered to be significant and indicated an infec-
tion. Likewise, in the capture IgA and IgM assays, a 2-fold or greater increase
in the antibody level exceeding the cut-off level of seropositivity was consid-
ered to indicate an infection. In the capture assays, the cut-off level of
seropositivity was determined to be 3 times the level obtained with conjugate
controls, which were included in each assay. Presence of enterovirus RNA was
taken as a marker of current infection.
During pregnancy, a 2-fold or greater increase in the antibody level between
the maternal sample taken at the end of the first trimester and the child’s cord
blood sample was considered to indicate an infection. A maternal IgM class
antibody level exceeding the previously described cut-off level was considered
to indicate an infection during the first months of pregnancy. In addition, the
presence of enterovirus RNA in the maternal sample or the cord blood sam-
ple was taken as a marker of enterovirus infection during the first months of
pregnancy or just before birth, respectively.
Evaluation of the amount of viral exposure. The occurrence of infections
was studied during 3 periods of follow-up, namely during the entire follow-up
of children, during a 6-month period just before the ﬁrst detection of autoan-
tibodies, and during pregnancy. The number of infections was adjusted to
either the number of children (the 6-month period and intrauterine period) or
the number of follow-up sample intervals in each child (frequency of infections
during the entire follow-up). The latter was used to eliminate the possible
confounding effect of minor variations in the frequency of sampling, because
the frequency of sampling is correlated with the probability of detecting
viremia and/or signiﬁcant increase in antibody level. Sample intervals were
taken as basic units of follow-up.
Autoantibody analyses. ICA, GADA, and protein tyrosine phosphatase-
related IA-2 molecule (IA-2A) were analyzed as described (17,18). IAA levels
were measured with a recently described microassay (19). The detection
limit of ICA was 2.5 JDFU. The cut-off limits for positivity for IAA, GADA, and
IA-2A were set at the 99th percentile (1.56 RU for IAA, 5.35 RU for GADA, and
0.43 RU for IA-2A) in more than 370 nondiabetic Finnish children. All samples
resulting in an antibody level between the 97.5th and the 99.5th percentiles
were reanalyzed to confirm antibody negativity or positivity.
Statistical analyses. Possible differences in the infection frequencies
between the case subjects and the control subjects were tested using the
2-tailed paired Student’s t test. Differences in the occurrence of infections
between the case and control children during the 6-month period before the
first detection of autoantibodies and the difference in the occurrence of in
utero infections between the case and control children was assessed using the
Mantel-Haenszel odds ratio (multiple and varying number of control subjects
per case) using Stata statistical software. The differences in the number of
infections among case subjects before seroconversion to autoantibody posi-
tivity versus the other sample intervals during the follow-up were tested using
the  
2 test or Fisher’s exact test.
RESULTS
Enterovirus infections during the entire follow-up of
children. Enterovirus infections were diagnosed during
the entire observation period in 26% (33 of 125) of the sample
intervals in the case subjects and in 18% (103 of 567) of1316 DIABETES, VOL. 49, AUGUST 2000
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those in the control children (P = 0.03) (Fig. 1 and 2A).
Enterovirus RNA was detected in 4% of the samples from the
case subjects and in 3% of the samples from the control chil-
dren (P = 0.8). Sex had no effect on the frequency of
enterovirus infections among case subjects (P = 0.5) or con-
trol subjects (P = 0.8), but the difference in the frequency of
enterovirus infections between the case and control groups
was more marked among boys (28 vs. 18%, P = 0.02) than
among girls (23 vs. 18%, P = 0.3). Only 2 of 33 (6%) and 9 of
103 (9%) enterovirus infections were diagnosed before the
age of 6 months in the case subjects and control subjects,
respectively. Enterovirus infections occurred as frequently
in children with the HLA-DQB1*02/*0302 genotype as in
children with the *0302/x genotype (P= 0.5 for the difference
among the case subjects, P = 0.3 for the difference among
the control subjects).
Enterovirus infections 0–6 months before the ﬁrst
detection of autoantibodies. A 6-month follow-up period
preceding the appearance of autoantibodies in the case sub-
jects was analyzed separately to evaluate possible temporal
relationship between infections and the appearance of
autoantibodies. A matching 6-month period of each control
child was observed for comparison. Enterovirus infections
were detected in 12 of the 21 case children (57%) and in 32 of
the 104 control children (31%) (odds ratio [OR] 3.7, 95% CI
1.2–11.4) (Fig. 2B). The difference was even more marked
when the occurrence of enterovirus RNA was compared
between case and control children during this 6-month
period (RNA was detected in 29 of the case subjects vs. 6% of
the control subjects,OR 8.4, 95% CI 1.7–40.2) (Fig. 2C).
The 6-month follow-up period included 1 or 2 sample inter-
vals per each child. Among the case children, enterovirus
infections were detected in 36% of the sample intervals dur-
ing this 6-month period compared with 23% of all sample
intervals during the rest of the follow-up (P = 0.2). Also,
enterovirus RNA was detected more frequently during this
6-month period than during the rest of the follow-up of case
children (18 vs. 0% of samples, respectively, P = 0.0002).
Among the control children, the frequency of enterovirus
infections did not differ between the sample intervals of the
6-month period and the rest of the follow-up (enterovirus
infections: 20 vs. 17%, P = 0.5; detection of enterovirus RNA:
4 vs. 4%, P = 0.9).
Enterovirus infections during pregnancy.The occurrence
of enterovirus infections during pregnancy was evaluated using
the maternal serum samples as well as the cord blood samples.
FIG. 1. The sex (M/F) and the HLA-DQB1 alleles of each case child (n =
21) are shown on the left. The horizontal bars indicate the length of the
follow-up starting at birth. All case children were initially negative for
diabetes-associated autoantibodies ( ) but developed permanent
autoantibody positivity ( ). Five case children have progressed to
clinical type 1 diabetes ( ). Enterovirus infections occurring during the
follow-up are marked with +, and   + indicates infections in which
enterovirus RNA was detected.
FIG. 2. A: Frequency of enterovirus infections in the sample intervals
of the entire follow-up period of the case and control children. B:
Occurrence of enterovirus infections in the case studies and control
subjects during a 6-month observation period before the appearance
of the first autoantibodies in the case children. C: Enterovirus RNA
detection in the case subjects and control subjects during a 6-month
observation period before the appearance of the first autoantibodies
in the case children.
C
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Two mothers of the 21 case children (10%) and 17 mothers of
the 104 control children (16%) had had an enterovirus infection
during pregnancy (OR = 0.5, 95% CI 0.1–2.5).
Adenovirus infections. Adenovirus infection was detected
in 7% of the sample intervals in both the case subjects and the
control subjects (P = 0.9). Neither sex nor HLA-DQB1 geno-
types had an effect on the frequency of adenovirus infections.
The frequency of adenovirus infections did not differ between
the case subjects and the control subjects during the 6-month
period before the case subjects’ seroconversion to autoanti-
body positivity (P= 0.9). None of the 21 case children’s moth-
ers had had an adenovirus infection during pregnancy and only
3 mothers of the 104 control children had experienced an
adenovirus infection during pregnancy (P = 0.5).
DISCUSSION
The frequency of enterovirus infections during the entire fol-
low-up period was higher in the children who presented with
signs of  -cell autoimmunity than in their control subjects
matched for time of birth, sex, and the HLA-DQB alleles (P=
0.03). The case and control children had similar frequencies
of adenovirus infections, implying that the children who
developed autoantibodies are not more susceptible to viral
infections in general.
Speciﬁcally, enterovirus infections were more frequent in
the case children during the 6-month period preceding the
appearance of the ﬁrst diabetes-associated autoantibodies
than in the matched time interval for the control children
(OR 3.7, 95% CI 1.2–11.4). The difference between case
subjects and control subjects was even more pronounced
for enterovirus RNA detection during this interval (OR 8.4,
95% CI 1.7–40.2). In addition, positive enterovirus RNA
findings in case children were significantly clustered
around this 6-month period. This temporal association
between enterovirus infections and the onset of  -cell
autoimmunity, a phenomenon that has also been implicated
by our previous studies (5,6), is consistent with the hypoth-
esis that enteroviruses may be one of the factors initiating
autoimmunity. The relationship between enterovirus RNA in
serum and the appearance of autoantibodies is particularly
intriguing because RNA in serum is a marker of viremia
and viremia would allow the spreading of the virus to vari-
ous target organs, including the pancreas.
The HLA genes are potentially important regulators of the
immune responses directed against enteroviruses because
T-cell responses against enterovirus antigens differ between
children with different HLA alleles (21,22). Thus, the HLA-
deﬁned genetic background is a possible confounding factor
when immune responses against enteroviruses are studied.
It is also possible that the same HLA alleles confer increased
susceptibility to both enterovirus infections and type 1 dia-
betes. In our study, the possible confounding effect of the
HLA-DQB1 alleles was eliminated by the matching of HLA-
DQB1 alleles between the case and control children, and yet
the frequency of enterovirus infections differed between the
case subjects and control subjects.
Enteroviruses are among the most complex groups of
viruses when considering serological diagnosis because the
enterovirus genus comprises >60 different serotypes. Several
serological assays were used in our study to detect antibod-
ies against as many enterovirus serotypes as possible. Nev-
ertheless, it is likely that not all enterovirus infections were
detected by these assays. For infections caused by Cox-
sackie B serotypes, the sensitivity of the serological assays is
between 90 and 100%, but in the case of infections caused by
Coxsackie A and echovirus serotypes, the sensitivity is not
higher than 75%. An RT-PCR was also used to further
improve the diagnostic sensitivity. This RT-PCR assay detects
the RNA of all enteroviruses because the ampliﬁed sequence
is common to all known enteroviruses (16). However, all
enterovirus infections do not necessarily cause viremia, and
the assay result is also dependent on the moment of sampling
because the viremic period usually lasts only a few weeks at
most. Therefore, it is evident that only a fraction of
enterovirus infections was detected by the RT-PCR assay.
Despite all these problems regarding enterovirus diagnosis,
the setting for the diagnosis of enterovirus infections was
exceptionally good in this study because of the relatively
short sample intervals and the complementary qualities of the
serological assays and the RT-PCR assay.
It is not possible, at the present stage, to conclude whether
the observed enterovirus infections represent speciﬁc serotypes
or genetic cluster(s) of enteroviruses, because neither the
RT-PCR assay nor the serological assays used are speciﬁc for
any serotypes or genetic clusters. Previously, Coxsackie B virus
serotypes have most often been associated with type 1 dia-
betes, but also other serotypes may be diabetogenic (23–25).
In this study, the occurrence of enterovirus infections dur-
ing pregnancy did not differ between the case and control
groups. This observation is in contrast with previous reports
suggesting that enterovirus infections during pregnancy
increase the offspring’s risk to develop type 1 diabetes
(3,4,26). An explanation for this could be that different end
points were used in these studies (i.e., autoantibody positiv-
ity in this study and clinical diabetes in the previous studies).
Larger study series are obviously needed to assess whether
enterovirus infection during pregnancy truly affects the risk
of diabetes in the offspring.
The rapidly increasing incidence of type 1 diabetes in the
Western world calls for action, and vaccination against
enteroviruses has been proposed as one possible way to
decrease the incidence. Our ﬁndings support the hypothesis
that enterovirus infections are indeed a risk factor for the
development of  -cell autoimmunity, but as the mechanism
of enterovirus-induced autoimmunity is still unclear, more
detailed studies are needed before enterovirus vaccinations
may be used as a feasible approach in the prevention of type 1
diabetes.
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